The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Nemtabrutinib in R/R follicular lymphoma
In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, briefly discusses the efficacy and safety of nemtabrutinib in patients with relapsed/refractory (R/R) follicular lymphoma, which has been investigated in cohort G of the Phase II BELLWAVE-003 trial (NCT04728893). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
